Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. Evaluation during hospitalization three months after discharge

Journal of Bone and Joint Surgery

Volumn 81, Issue 7, 1999, Pages 932-940

  Colwell, Clifford W ^a   Collis, Dennis K ^b   Paulson, Rolf ^c   McCutchen, John W ^d   Bigler, Gregory T ^e   Lutz, Susan ^d   Hardwick, Mary E ^a  

^a SCRIPPS CLINIC   (United States)

^b Sacred Heart General Hospital   (United States)

^c Box 6003   (United States)

^d University Orthopaedics ^*  (United States)

^e University Orthopaedics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; WARFARIN;

ADULT; AGED; ANEMIA; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOEMBOLISM; TOTAL HIP PROSTHESIS;

EID: 0007040195     PISSN: 00219355     EISSN: None     Source Type: Journal    
DOI: 10.2106/00004623-199907000-00005     Document Type: Article

References (30)

1. Amstutz, H. C.; Friscia, D. A.; Dorey, F.; and Carney, B. T.: Warfarin prophylaxis to prevent mortality from pulmonary embolism after total hip replacement. J. Bone and Joint Surg., 71-A: 321-326, March 1989.
2. Amstutz, H. C; Grecula, M. J.; and Dorej, F.: Prevention of thromboembolic disease with warfarin. Sem. Arthroplasty, 3: 99-107, 1992.
3. Bergqvist, D.; Benoni, G.; Björgell, O.; Fredin, H.; Hedlundh, U.; Nicolas, S.; Nilsson, P.; and Nylander, G.: Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. New England J. Med., 335: 696-700, 1996.
4. Bergqvist, D.; Lindgren, B.; and Matzsch, T.: Comparison of the cost of preventing postoperative deep vein thrombosis with either unfractionated or low molecular weight heparin. British J. Surg., 83: 1548-1552, 1996.
5. Bunting, R. W.; Doppelt, S. H.; and Lavine, L. S.: Extreme thrombocytosis after orthopaedic surgery, J. Bone and Joint Surg., 73-B(4): 687-688, 1991.
6. Carter, C. A.; Skoutakis, V. A.; Spiro, T. E.; West, M. E.; Tooms, R. E.; Joe, R. H.; and Knutson, T. J.: Enoxaparin: the low-molecular-weight heparin for prevention of postoperative thromboembolic complications. Ann. Pharmacother., 27: 1223-1230, 1993.
7. Clagett, G. P.; Anderson, F. A., Jr.; Levine, M. N.; Salzman, E. W.; and Wheeler, H. B.: Prevention of venous thromboembolism. Chest, 102 (Supplement 4): 391S-407S, 1992.
8. Clagett, G. P.: Prevention of postoperative venous thromboembolism: an update. Am. J. Surg., 168: 515-522, 1994.
9. Clagett, G. P.; Anderson, F. A., Jr.; Heit, J.; Levine, M. N.; and Wheeler, H. B.: Prevention of venous thromboembolism. Chest, 108 (Supplement 4): 312S-334S, 1995.
10. Cola, C., and Ansell, J.: Heparin-induced thrombocytopenia and arterial thrombosis: alternative therapies. Am. Heart J., 119: 368-374, 1990.
11. Colwell, C. W., Jr.; Spiro, T. E.; Trowbridge, A. A.; Morris, B. A.; Kwaan, H. C.; Blaha, J. D.; Comerota, A. J.; and Skoutakis, V. A.: Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy and safety. J. Bone and Joint Surg., 76-A: 3-14, Jan. 1994.
12. Colwell, C. W., Jr., and Spiro, T. E.: Efficacy and safety of enoxaparin to prevent deep vein thrombosis after hip arthroplasty. Clin. Orthop., 319:215-222, 1995.
13. Eckman, M. H.; Levine, H. J.; and Pauker, S. G.: Effect of laboratory variation in the prothrombin-time ratio on the results of oral anticoagulant therapy. New England J. Med., 329: 696-702, 1993.
14. Gillings, D., and Koch, G.: The application of the principle of intention-to-treat to the analysis of clinical trials. Drug Info. J., 25: 411-424, 1991.
15. Haake, D. A., and Berkman, S. A.: Venous thromboembolic disease after hip surgery. Risk factors, prophylaxis and diagnosis. Clin. Orthop., 242: 212-231, 1989.
16. Harris, W. H.; Salzman, E. W.; Athanasoulis, C.; Waltman, A. C.; Baum, S.; and DeSanctis, R. W.: Comparison of warfarin, low-molecular-weight dextran, aspirin, and subcutaneous heparin in prevention of venous thromboembolism following total hip replacement. J. Bone and Joint Surg., 56-A: 1552-1562. Dec. 1974.
17. Hawkins, D. W.; Langley, P. C.; and Krueger, K. P.: A pharmacoeconomic assessment of enoxaparin and warfarin as prophylaxis for deep vein thrombosis in patients undergoing knee replacement sugery. Clin. Ther., 20: 182-195, 1998.
18. Hirsh. J.; Dalen, J. E.; Deykin, D.; and Poller, L.: Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest, 102 (Supplement 4): 312S-326S, 1992.
19. Hirsh, J., and Levine, M. N.: Low molecular weight heparin. Blood, 79: 1-17, 1992.
20. Hosmer, D. W., Jr., and Lemeshow, S.: Applied Logistic Regression. New York, Wiley, 1989.
21. National Institutes of Health Consensus Development Conference: Prevention of venous thrombosis and pulmonary embolism. NIH Consensus Development. J. Am. Med. Assn., 256: 744-749, 1986.
22. Paiement, G.; Wessinger, S. J.; Waitman, A. C.; and Harris, W. H.: Low-dose warfarin versus external pneumatic compression for prophylaxis against venous thromboembolism following total hip replacement. J. Arthroplasty, 2: 23-26, 1987.
23. Planes, A.; Vochelle, N.; Darmon, J. Y.; Fagola, M.; Bellaud, M.; and Huet, Y.: Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. Lancet, 348: 224-228, 1996.
24. Salzman, E. W.: Progress in preventing venous thromboembolism [editorial]. New England J. Med., 309: 980-982, 1983.
25. Schmitt, B. P., and Adelman, B.: Heparin-associated thrombocytopema: a critical review and pooled analysis. Am. J. Med. Sci., 305: 208-215, 1993.
26. Sikorski, J. M.; Hampson, W. G.; and Staddon, G. E.: The natural history and aetiology of deep vein thrombosis after total hip replacement. J. Bone and Joint Surg., 63-B(2): 171-177, 1981.
27. Stamatakis, J. D.; Kakkar, V. V.; Sagar, S.; Lawrence, D.; Nairn, D.; and Bentley, P. G.: Femoral vein thrombosis and total hip replacement. British Med. J., 2: 223-225, 1977.
28. Turpie, A. G.; Levine, M. N.; Hirsh, J.; Carter, C. J.; Jay, R. M.; Powers, P. J.; Andrew, M.; Hull, R. D.; and Gent, M.: A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. New England J. Med., 315: 925-929, 1986.
29. Wade, W. E.; Taylor, A. T.; and Spruill, W. J.: Using published, institutional data to evaluate the cost effectiveness of DVT prophylaxis. Formulary, 31: 1203-1210, 1996.
30. Warkentin, T. E.; Levine, M. N.; Hirsh, J.; Horsewood, P.; Roberts, R. S.; Gent, M.; and Kelton, L. G.: Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. New England J. Med., 332: 1330-1335, 1995.